TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A small, open-label trial found that an inflammatory index was lower at each measured follow-up after psilocybin therapy in people with Parkinson’s disease and mood dysfunction. The findings do not show that psilocybin treats Parkinson’s or that the biomarker changes caused clinical benefits; researchers say larger randomized trials are needed.
A small, nonrandomized trial in people with Parkinson’s disease and mood dysfunction found that a measure of systemic inflammation was lower after psilocybin therapy, with the difference still present 30 days after the higher dose. The study involved 12 participants, and its authors said the findings are preliminary and need testing in larger randomized trials; they do not establish that psilocybin reduces Parkinson’s symptoms through changes in inflammation.
Ellen Bradley, MD, of the University of California, San Francisco, and colleagues studied 12 people ages 40 to 75 with mild-to-moderate Parkinson’s disease. In the open-label trial, participants received oral synthetic psilocybin at 10 mg and 25 mg, about two weeks apart. Researchers collected and analyzed plasma samples from nine participants at baseline, one day after each dose, and 30 days after the 25-mg dose.
The primary inflammation measure was a proinflammatory index calculated from levels of IL-6, IL-8, tumor necrosis factor alpha, interferon gamma, and high-sensitivity C-reactive protein. Compared with baseline, the index was significantly lower one day after the 10-mg dose, with a standard mean difference (SMD) of -0.72 (adjusted P=0.003). It was also lower one day after 25 mg (SMD -0.60; adjusted P=0.02) and 30 days after 25 mg (SMD -0.62; adjusted P=0.047), according to the research letter in JAMA Psychiatry.
Some individual markers did not follow the same pattern at every measurement. IL-6 was significantly lower, and IL-10 significantly higher, one day after the 10-mg dose, but neither result was significant at other time points. The mitochondrial-stress marker GDF-15 was lower one day after each dose, but not at the 30-day measurement. FGF-21 rose one day after each dose, though that increase was not statistically significant.
What the Biomarker Findings Could Mean
The results add early biological data to research on psilocybin beyond psychiatric conditions. Parkinson’s disease affects movement and can also involve mood symptoms; understanding whether a treatment is associated with changes in inflammation or cellular stress could help researchers investigate how its effects occur. But these measurements are biomarkers, not evidence of disease modification, and this trial cannot show that changes in them led to better health outcomes.
The report follows a parent trial in which psilocybin therapy was associated with reductions in depression, anxiety, and motor symptoms among participants with Parkinson’s, according to the source report. The biomarker findings may give researchers questions to test alongside clinical outcomes. They do not, on their own, establish a treatment benefit, demonstrate that inflammation is a cause of symptoms, or show that psilocybin is safe and effective for people with Parkinson’s more broadly.
Small samples and a nonrandomized, open-label design make the findings difficult to generalize. Without a comparison group, the researchers cannot rule out other explanations for the observed changes, including normal variation over time. The limited number of samples—nine participants—also means the estimates need confirmation in a larger group.
psilocybin capsules for mood support
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How This Fits Parkinson’s Research
The work was reported by MedPage Today on October 21, 2026, and published as a research letter in JAMA Psychiatry. The researchers described it as the first report, to their knowledge, of changes in these types of biological markers after psychedelic treatment in people with a neurodegenerative disease. That is a statement about the report’s place in the literature, not proof that the observed effects are unique or established.
Psilocybin studies have more commonly examined mental health conditions such as depression, anxiety, and addiction. Albert Garcia-Romeu, PhD, of Johns Hopkins University School of Medicine, who was not involved in the trial, told MedPage Today that the Parkinson’s study adds evidence of possible effects on inflammation and mitochondrial-stress markers. He also pointed to other research into potential biological effects of psychedelics, including animal work on chemotherapy-related nerve damage; that separate work does not verify a benefit in people with Parkinson’s.
The Parkinson’s findings are also related to a prior trial of psilocybin therapy in this patient group, which reported associations with changes in depression, anxiety, and motor symptoms. The current biomarker analysis addresses a different question: whether selected blood measures changed after dosing. It does not establish how those measures relate to the clinical observations.
“To our knowledge, this is the first report of changes in these types of markers after psychedelic treatment in people with a neurodegenerative disease.”
— Ellen Bradley, MD, University of California, San Francisco, speaking to MedPage Today
anti-inflammatory supplements for Parkinson's
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Questions the Small Trial Cannot Answer
The study does not establish whether psilocybin caused the biomarker changes, because it was open-label and had no randomized control group. Its sample was small, and blood samples were available from only nine of the 12 participants. The report also does not establish whether the measured changes persist beyond 30 days or whether they are meaningful to patients’ symptoms or longer-term disease course.
It remains unclear whether the findings will be reproduced in a larger, controlled trial, what biological processes might explain them, and whether the inflammation and mitochondrial-stress measures are connected to any clinical effects. The source report does not provide enough information to determine how broadly the findings apply to people with Parkinson’s who do not have mood dysfunction, or to people with different disease severity.
The results should not be read as evidence that psilocybin is an approved or proven treatment for Parkinson’s disease. The study reports measured changes after therapy; it does not settle the treatment’s benefits, risks, or appropriate use.
As an affiliate, we earn on qualifying purchases.
Randomized Parkinson’s Study Underway
O’Donovan told MedPage Today that the UCSF team is following up with a randomized controlled trial in people with Parkinson’s disease, including more in-depth analyses of inflammation and mitochondrial stress. A controlled design can help determine whether the changes seen in the small open-label study are attributable to psilocybin rather than other factors. The source report did not give a completion date or additional results from that trial.
Garcia-Romeu also described a separate study of psilocybin in people with mild cognitive impairment or early-stage Alzheimer’s disease and depression. At the time of the report, his team had treated 18 people and enrolled 19 of a target of 20; he said the researchers planned to complete the trial and publish findings the following year. That study is separate from the Parkinson’s research and will not directly confirm its results.
For the Parkinson’s findings, the next key evidence will be results from larger randomized research that reports both biomarker measurements and patient outcomes. Until those data are available, the reported inflammation changes remain an early observation rather than proof of a clinical benefit.
biomarker testing kits for inflammation
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the Parkinson’s psilocybin trial find?
In a small open-label study, a systemic inflammation index was significantly lower than baseline one day after both psilocybin doses and 30 days after the 25-mg dose. Some mitochondrial-stress marker changes were short-lived or not statistically significant.
How many people took part?
The trial included 12 people with mild-to-moderate Parkinson’s disease and mood dysfunction, ages 40 to 75. Plasma samples used for the biomarker analysis were collected from nine participants.
Does this show psilocybin treats Parkinson’s disease?
No. The study was small and nonrandomized, and it measured biological markers after treatment. It does not prove that psilocybin treats Parkinson’s, slows disease progression, or causes clinical improvements through reduced inflammation.
What happens next in the research?
The UCSF researchers said they are conducting a randomized controlled trial in people with Parkinson’s, with further analysis of inflammation and mitochondrial-stress markers. Results and a completion timeline were not provided in the report.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
